Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2016

Open Access 01-12-2016 | Research article

Resilience of a FIT screening programme against screening fatigue: a modelling study

Authors: Marjolein J. E. Greuter, Johannes Berkhof, Karen Canfell, Jie-Bin Lew, Evelien Dekker, Veerle M. H. Coupé

Published in: BMC Public Health | Issue 1/2016

Login to get access

Abstract

Background

Repeated participation is important in faecal immunochemical testing (FIT) screening for colorectal cancer (CRC). However, a large number of screening invitations over time may lead to screening fatigue and consequently, decreased participation rates. We evaluated the impact of screening fatigue on overall screening programme effectiveness.

Methods

Using the ASCCA model, we simulated the Dutch CRC screening programme consisting of biennial FIT screening in individuals aged 55–75. We studied the resilience of the programme against heterogeneity in screening attendance and decrease in participation rate due to screening fatigue. Outcomes were reductions in CRC incidence and mortality compared to no screening.

Results

Assuming a homogenous 63 % participation, i.e., each round each individual was equally likely to attend screening, 30 years of screening reduced CRC incidence and mortality by 39 and 53 %, respectively, compared to no screening. When assuming clustered participation, i.e., three subgroups of individuals with a high (95 %), moderate (65 %) and low (5 %) participation rate, screening was less effective; reductions were 33 % for CRC incidence and 43 % for CRC mortality. Screening fatigue considerably reduced screening effectiveness; if individuals refrained from screening after three negative screens, model-predicted incidence reductions decreased to 25 and 18 % under homogenous and clustered participation, respectively. Figures were 34 and 25 % for mortality reduction.

Conclusions

Screening will substantially decrease CRC incidence and mortality. However, screening effectiveness can be seriously compromised if screening fatigue occurs. This warrants careful monitoring of individual screening behaviour and consideration of targeted invitation systems in individuals who have (repeatedly) missed screening rounds.
Literature
1.
2.
de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AHC, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107:1570–8.CrossRefPubMed
3.
Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–70.CrossRefPubMed
4.
Hundt S, Haug U, Brenner H. Comparative Evaluation of Immunochemical Fecal Occult Blood Tests for Colorectal Adenoma Detection. Ann Intern Med. 2009;150:162–9.CrossRefPubMed
5.
Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171.CrossRefPubMedPubMedCentral
6.
Stegeman I, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers E, Elferink MA, Stegeman I, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers E, Elferink MAG, et al. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol. 2015;39:388–93.CrossRefPubMed
7.
Kapidzic A, Grobbee EJ, Hol L, van Roon AH, van Vuuren AJ, Spijker W, et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol. 2014;109:1257–64.CrossRefPubMed
8.
Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol. 2012;10:633–8.CrossRefPubMed
9.
Marteau T, Kinmonth A, Thompson S, Pyke S. The psychological impact of cardiovascular screening and intervention in primary care: a problem of false reassurance? Br J Gen Pract. 1996;46:577–82.PubMedPubMedCentral
10.
11.
Greuter MJ, Xu X-M, Lew J-B, Dekker E, Kuipers EJ, Canfell K, et al. Modelling the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA). Risk Anal. 2014;34:889–910.CrossRefPubMed
12.
Rijksinstituut voor Volksgezondheid en Milieu. Factsheet Bevolkingsonderzoek Darmkanker. 2015.
13.
Nederlandse Vereniging van Maag-, Darm- en Leverartsen. Nederlandse Richtlijn Coloscopie Surveillance. 2013.
14.
van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population. Gastroenterology. 2008;135:82–90.CrossRefPubMed
15.
van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101:343–50.CrossRefPubMed
16.
Denters MJ, Deutekom M, Bossuyt PM, van Rijn AF, Fockens P, Dekker E. Involvement of previous non-participants cannot fully compensate for lower participation in a second round of FIT-screening. Cancer Epidemiol. 2013;37:330–5.CrossRefPubMed
17.
18.
Senore C, Inadomi J, Segnan N, Bellisario C, Hassan C. Optimising colorectal cancer screening acceptance: a review. Gut. 2015;64:1158–77.CrossRefPubMed
19.
Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM. Development of new non-invasive tests for colorectal cancer screening: The relevance of information on adenoma detection. Int J Cancer J Int Cancer. 2015;136(12):2864–74.CrossRef
20.
Wilschut JA, Hol L, Dekker E, Jansen JB, Van Leerdam ME, Lansdorp-Vogelaar I, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology. 2011;141:1648–55.e1.CrossRefPubMed
21.
Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JCIY, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62–8.CrossRefPubMed
22.
IARC Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J (Clin Res Ed). 1986;293:659–64.CrossRef
23.
Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br. J. Cancer. 1996;73:1001–5.CrossRef
24.
Coldman A, Phillips N, Kan L, Matisic J, Benedet L, Towers L. Risk of invasive cervical cancer after three consecutive negative Pap smears. J Med Screen. 2003;10:196–200.CrossRefPubMed
25.
Castañón A, Landy R, Cuzick J, Sasieni P. Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. PLoS Med. 2014;11(1):e1001585.CrossRefPubMedPubMedCentral
26.
U.S. Preventive Services Task Force. Cervical cancer: screening. 2012.
27.
Care CTF on PH. Recommendations on screening for cervical cancer. Can Med Assoc J. 2013;185:35–45.CrossRef
28.
Australian government - department of health. National cervical screening program. 2005.
29.
Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination: Evidence for a 10-year interval between colonoscopies. JAMA. 2006;295:2366–73.CrossRefPubMed
30.
31.
Cunningham D, Atkin W, Lenz H-J, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375:1030–47.CrossRefPubMed
32.
Hastert TA, Beresford SAA, Sheppard L, White E. Disparities in cancer incidence and mortality by area-level socioeconomic status: a multilevel analysis. J Epidemiol Community Health. 2015;69(2):168–76.CrossRefPubMed
33.
Steele RJC, Kostourou I, McClements P, Watling C, Libby G, Weller D, et al. Effect of gender, age and deprivation on key performance indicators in a FOBT-based colorectal screening programme. J Med Screen. 2010;17:68–74.CrossRefPubMed
Metadata
Title
Resilience of a FIT screening programme against screening fatigue: a modelling study
Authors
Marjolein J. E. Greuter
Johannes Berkhof
Karen Canfell
Jie-Bin Lew
Evelien Dekker
Veerle M. H. Coupé
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2016
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-016-3667-8

Other articles of this Issue 1/2016

BMC Public Health 1/2016 Go to the issue

Research article

Overweight and obesity among women: analysis of demographic and health survey data from 32 Sub-Saharan African Countries

Research article

An equity analysis of utilization of health services in Afghanistan using a national household survey

Research article

Associations between lifestyle behaviours and optimal wellbeing in a diverse sample of New Zealand adults

Research article

Assessing health literacy in the eastern and middle-eastern cultures

Research article

Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone

Research article

Predictors of Chlamydia Trachomatis testing: perceived norms, susceptibility, changes in partner status, and underestimation of own risk